RGLS4326 Confers Efficacy and Modulate Aberrant Signaling and Metabolic Pathways in PKD Mouse Models. RGLS4326 Confers Efficacy and Modulate Aberrant Signaling and Metabolic Pathways in PKD Mouse Models Post navigation Previous: Urine and blood biomarkers correlate with rate of eGFR decline in Alport syndrome: The ATHENA StudyNext: Preclinical Development of miR-10B Antagonist for the Treatment of Glioblastoma
